The page could not be loaded. The CMS.gov Web site currently does not fully support browsers with
Medicare covers certain colorectal cancer screening tests and procedures for Medicare beneficiaries that meet certain eligibility criteria, as authorized by Sections 1861(s)(2)(R) and 1861(pp) of the Social Security Act and regulations at 42 CFR 410.37. Under 42 CFR 410.37(a)(2), CMS is allowed to add coverage of other colorectal cancer screening tests or procedures through a national coverage determination, with such frequency and payment limits as CMS determines appropriate, in consultation with appropriate organizations.
CMS received a formal request for a national coverage determination from Epigenomics to consider coverage of Epi proColon®- one example of a blood-based biomarker screening test for colorectal cancer.
CMS is soliciting public comment relevant to the request. We are particularly interested in comments that include scientific evidence and that address appropriate test characteristics of colorectal cancer screening tests.
February 28, 2020
CMS initiates this national coverage analysis for screening for colorectal cancer using Epi proColon; a blood-based test . The initial 30-day public comment period begins with this posting date, and ends after 30 calendar days. CMS considers all public comments, and is particularly interested in clinical studies and other scientific information relevant to the topic under review.
Instructions on submitting comments can be found at: http://www.cms.gov/Medicare/Coverage/InfoExchange/publiccomments.html.
To submit a comment, please use the orange "Comment" button at the top of the page. Enter comments directly into the "Submit A Public Comment" webpage.
October 16, 2020